The hypothalamic–pituitary–adrenal axis in childhood cancer survivors

Endocrine abnormalities are common among childhood cancer survivors. Abnormalities of the hypothalamic–pituitary–adrenal axis (HPAA) are relatively less common, but the consequences are severe if missed. Patients with tumours located and/or had surgery performed near the hypothalamic–pituitary regio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Endocrine-related cancer 2018-10, Vol.25 (10), p.R479-R496
Hauptverfasser: Wei, Christina, Crowne, Elizabeth C
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page R496
container_issue 10
container_start_page R479
container_title Endocrine-related cancer
container_volume 25
creator Wei, Christina
Crowne, Elizabeth C
description Endocrine abnormalities are common among childhood cancer survivors. Abnormalities of the hypothalamic–pituitary–adrenal axis (HPAA) are relatively less common, but the consequences are severe if missed. Patients with tumours located and/or had surgery performed near the hypothalamic–pituitary region and those treated with an accumulative cranial radiotherapy dose of over 30 Gy are most at risk of adrenocorticotrophic hormone (ACTH) deficiency. Primary adrenal insufficiency may occur in patients with tumours located in or involving one or both adrenals. The effects of adjunct therapies also need to be considered, particularly, new immunotherapies. High-dose and/or prolonged courses of glucocorticoid treatment can result in secondary adrenal insufficiency, which may take months to resolve and hence reassessment is important to ensure patients are not left on long-term replacement steroids inappropriately. The prevalence and cumulative incidences of HPAA dysfunction are difficult to quantify because of its non-specific presentation and lack of consensus regarding its investigations. The insulin tolerance test remains the gold standard for the diagnosis of central cortisol deficiency, but due to its risks, alternative methods with reduced diagnostic sensitivities are often used and must be interpreted with caution. ACTH deficiency may develop many years after the completion of oncological treatment alongside other pituitary hormone deficiencies. It is essential that health professionals involved in the long-term follow-up of childhood cancer survivors are aware of individuals at risk of developing HPAA dysfunction and implement appropriate monitoring and treatment.
doi_str_mv 10.1530/ERC-18-0217
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2054952739</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2054952739</sourcerecordid><originalsourceid>FETCH-LOGICAL-b396t-30ca7e089caa6d6b292a4915cfdd46f0728080baecada3e064fa380a8c87e1653</originalsourceid><addsrcrecordid>eNp90M9KxDAQBvAgiuu_k3cpeBGkOkmbNjnKsurCgiB6LtM0pZG2WZN2cW--g2_ok5hl1YMHD8PM4ccH8xFySuGK8gSuZ4_TmIoYGM13yAFNcxlngtHdcCecxgBCTMih9y8AkAnO98mESSE5Z_yAzJ8aHTXrpR0abLEz6vP9Y2mG0Qzo1uHGyuke2wjfjI9MH6nGtFVjbRUp7JV2kR_dyqys88dkr8bW65PvfUSeb2dP0_t48XA3n94s4jKR2RAnoDDXIKRCzKqsZJJhKilXdVWlWQ05EyCgRK2wwkRDltaYCEChRK5pxpMjcrHNXTr7Omo_FJ3xSrct9tqOvmDAU8lZnshAz__QFzu68E5QlLIwEvKgLrdKOeu903WxdKYL7xcUik3DRWi4oKLYNBz02XfmWHa6-rU_lQZAt6A01iuj-8HURuG_oV8QGIhP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2112211907</pqid></control><display><type>article</type><title>The hypothalamic–pituitary–adrenal axis in childhood cancer survivors</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><source>Society for Endocrinology Journals</source><creator>Wei, Christina ; Crowne, Elizabeth C</creator><creatorcontrib>Wei, Christina ; Crowne, Elizabeth C</creatorcontrib><description>Endocrine abnormalities are common among childhood cancer survivors. Abnormalities of the hypothalamic–pituitary–adrenal axis (HPAA) are relatively less common, but the consequences are severe if missed. Patients with tumours located and/or had surgery performed near the hypothalamic–pituitary region and those treated with an accumulative cranial radiotherapy dose of over 30 Gy are most at risk of adrenocorticotrophic hormone (ACTH) deficiency. Primary adrenal insufficiency may occur in patients with tumours located in or involving one or both adrenals. The effects of adjunct therapies also need to be considered, particularly, new immunotherapies. High-dose and/or prolonged courses of glucocorticoid treatment can result in secondary adrenal insufficiency, which may take months to resolve and hence reassessment is important to ensure patients are not left on long-term replacement steroids inappropriately. The prevalence and cumulative incidences of HPAA dysfunction are difficult to quantify because of its non-specific presentation and lack of consensus regarding its investigations. The insulin tolerance test remains the gold standard for the diagnosis of central cortisol deficiency, but due to its risks, alternative methods with reduced diagnostic sensitivities are often used and must be interpreted with caution. ACTH deficiency may develop many years after the completion of oncological treatment alongside other pituitary hormone deficiencies. It is essential that health professionals involved in the long-term follow-up of childhood cancer survivors are aware of individuals at risk of developing HPAA dysfunction and implement appropriate monitoring and treatment.</description><identifier>ISSN: 1351-0088</identifier><identifier>EISSN: 1479-6821</identifier><identifier>DOI: 10.1530/ERC-18-0217</identifier><identifier>PMID: 29895525</identifier><language>eng</language><publisher>England: Bioscientifica Ltd</publisher><subject>Adrenal glands ; Adrenocorticotropic hormone ; Cancer ; Children ; Glucocorticoids ; Hypothalamic-pituitary-adrenal axis ; Hypothalamus ; Immunotherapy ; Insulin ; Medical personnel ; Patients ; Pituitary ; Pituitary hormones ; Radiation therapy ; Review ; Steroid hormones ; Surgery ; Tumors</subject><ispartof>Endocrine-related cancer, 2018-10, Vol.25 (10), p.R479-R496</ispartof><rights>2018 Society for Endocrinology</rights><rights>2018 Society for Endocrinology.</rights><rights>Copyright Society for Endocrinology &amp; BioScientifica Ltd. Oct 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b396t-30ca7e089caa6d6b292a4915cfdd46f0728080baecada3e064fa380a8c87e1653</citedby><cites>FETCH-LOGICAL-b396t-30ca7e089caa6d6b292a4915cfdd46f0728080baecada3e064fa380a8c87e1653</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,3950,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29895525$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wei, Christina</creatorcontrib><creatorcontrib>Crowne, Elizabeth C</creatorcontrib><title>The hypothalamic–pituitary–adrenal axis in childhood cancer survivors</title><title>Endocrine-related cancer</title><addtitle>Endocr Relat Cancer</addtitle><description>Endocrine abnormalities are common among childhood cancer survivors. Abnormalities of the hypothalamic–pituitary–adrenal axis (HPAA) are relatively less common, but the consequences are severe if missed. Patients with tumours located and/or had surgery performed near the hypothalamic–pituitary region and those treated with an accumulative cranial radiotherapy dose of over 30 Gy are most at risk of adrenocorticotrophic hormone (ACTH) deficiency. Primary adrenal insufficiency may occur in patients with tumours located in or involving one or both adrenals. The effects of adjunct therapies also need to be considered, particularly, new immunotherapies. High-dose and/or prolonged courses of glucocorticoid treatment can result in secondary adrenal insufficiency, which may take months to resolve and hence reassessment is important to ensure patients are not left on long-term replacement steroids inappropriately. The prevalence and cumulative incidences of HPAA dysfunction are difficult to quantify because of its non-specific presentation and lack of consensus regarding its investigations. The insulin tolerance test remains the gold standard for the diagnosis of central cortisol deficiency, but due to its risks, alternative methods with reduced diagnostic sensitivities are often used and must be interpreted with caution. ACTH deficiency may develop many years after the completion of oncological treatment alongside other pituitary hormone deficiencies. It is essential that health professionals involved in the long-term follow-up of childhood cancer survivors are aware of individuals at risk of developing HPAA dysfunction and implement appropriate monitoring and treatment.</description><subject>Adrenal glands</subject><subject>Adrenocorticotropic hormone</subject><subject>Cancer</subject><subject>Children</subject><subject>Glucocorticoids</subject><subject>Hypothalamic-pituitary-adrenal axis</subject><subject>Hypothalamus</subject><subject>Immunotherapy</subject><subject>Insulin</subject><subject>Medical personnel</subject><subject>Patients</subject><subject>Pituitary</subject><subject>Pituitary hormones</subject><subject>Radiation therapy</subject><subject>Review</subject><subject>Steroid hormones</subject><subject>Surgery</subject><subject>Tumors</subject><issn>1351-0088</issn><issn>1479-6821</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp90M9KxDAQBvAgiuu_k3cpeBGkOkmbNjnKsurCgiB6LtM0pZG2WZN2cW--g2_ok5hl1YMHD8PM4ccH8xFySuGK8gSuZ4_TmIoYGM13yAFNcxlngtHdcCecxgBCTMih9y8AkAnO98mESSE5Z_yAzJ8aHTXrpR0abLEz6vP9Y2mG0Qzo1uHGyuke2wjfjI9MH6nGtFVjbRUp7JV2kR_dyqys88dkr8bW65PvfUSeb2dP0_t48XA3n94s4jKR2RAnoDDXIKRCzKqsZJJhKilXdVWlWQ05EyCgRK2wwkRDltaYCEChRK5pxpMjcrHNXTr7Omo_FJ3xSrct9tqOvmDAU8lZnshAz__QFzu68E5QlLIwEvKgLrdKOeu903WxdKYL7xcUik3DRWi4oKLYNBz02XfmWHa6-rU_lQZAt6A01iuj-8HURuG_oV8QGIhP</recordid><startdate>201810</startdate><enddate>201810</enddate><creator>Wei, Christina</creator><creator>Crowne, Elizabeth C</creator><general>Bioscientifica Ltd</general><general>Society for Endocrinology &amp; BioScientifica Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>201810</creationdate><title>The hypothalamic–pituitary–adrenal axis in childhood cancer survivors</title><author>Wei, Christina ; Crowne, Elizabeth C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b396t-30ca7e089caa6d6b292a4915cfdd46f0728080baecada3e064fa380a8c87e1653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adrenal glands</topic><topic>Adrenocorticotropic hormone</topic><topic>Cancer</topic><topic>Children</topic><topic>Glucocorticoids</topic><topic>Hypothalamic-pituitary-adrenal axis</topic><topic>Hypothalamus</topic><topic>Immunotherapy</topic><topic>Insulin</topic><topic>Medical personnel</topic><topic>Patients</topic><topic>Pituitary</topic><topic>Pituitary hormones</topic><topic>Radiation therapy</topic><topic>Review</topic><topic>Steroid hormones</topic><topic>Surgery</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wei, Christina</creatorcontrib><creatorcontrib>Crowne, Elizabeth C</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Endocrine-related cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wei, Christina</au><au>Crowne, Elizabeth C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The hypothalamic–pituitary–adrenal axis in childhood cancer survivors</atitle><jtitle>Endocrine-related cancer</jtitle><addtitle>Endocr Relat Cancer</addtitle><date>2018-10</date><risdate>2018</risdate><volume>25</volume><issue>10</issue><spage>R479</spage><epage>R496</epage><pages>R479-R496</pages><issn>1351-0088</issn><eissn>1479-6821</eissn><abstract>Endocrine abnormalities are common among childhood cancer survivors. Abnormalities of the hypothalamic–pituitary–adrenal axis (HPAA) are relatively less common, but the consequences are severe if missed. Patients with tumours located and/or had surgery performed near the hypothalamic–pituitary region and those treated with an accumulative cranial radiotherapy dose of over 30 Gy are most at risk of adrenocorticotrophic hormone (ACTH) deficiency. Primary adrenal insufficiency may occur in patients with tumours located in or involving one or both adrenals. The effects of adjunct therapies also need to be considered, particularly, new immunotherapies. High-dose and/or prolonged courses of glucocorticoid treatment can result in secondary adrenal insufficiency, which may take months to resolve and hence reassessment is important to ensure patients are not left on long-term replacement steroids inappropriately. The prevalence and cumulative incidences of HPAA dysfunction are difficult to quantify because of its non-specific presentation and lack of consensus regarding its investigations. The insulin tolerance test remains the gold standard for the diagnosis of central cortisol deficiency, but due to its risks, alternative methods with reduced diagnostic sensitivities are often used and must be interpreted with caution. ACTH deficiency may develop many years after the completion of oncological treatment alongside other pituitary hormone deficiencies. It is essential that health professionals involved in the long-term follow-up of childhood cancer survivors are aware of individuals at risk of developing HPAA dysfunction and implement appropriate monitoring and treatment.</abstract><cop>England</cop><pub>Bioscientifica Ltd</pub><pmid>29895525</pmid><doi>10.1530/ERC-18-0217</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1351-0088
ispartof Endocrine-related cancer, 2018-10, Vol.25 (10), p.R479-R496
issn 1351-0088
1479-6821
language eng
recordid cdi_proquest_miscellaneous_2054952739
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection; Society for Endocrinology Journals
subjects Adrenal glands
Adrenocorticotropic hormone
Cancer
Children
Glucocorticoids
Hypothalamic-pituitary-adrenal axis
Hypothalamus
Immunotherapy
Insulin
Medical personnel
Patients
Pituitary
Pituitary hormones
Radiation therapy
Review
Steroid hormones
Surgery
Tumors
title The hypothalamic–pituitary–adrenal axis in childhood cancer survivors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T07%3A22%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20hypothalamic%E2%80%93pituitary%E2%80%93adrenal%20axis%20in%20childhood%20cancer%20survivors&rft.jtitle=Endocrine-related%20cancer&rft.au=Wei,%20Christina&rft.date=2018-10&rft.volume=25&rft.issue=10&rft.spage=R479&rft.epage=R496&rft.pages=R479-R496&rft.issn=1351-0088&rft.eissn=1479-6821&rft_id=info:doi/10.1530/ERC-18-0217&rft_dat=%3Cproquest_cross%3E2054952739%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2112211907&rft_id=info:pmid/29895525&rfr_iscdi=true